InVivo Therapeutics (NVIVQ) 10-Q2018 Q1 Quarterly report

Filed: 7 May 18, 4:03pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. junior Avg

New words: advisor, analyst, analyzed, appointed, appointment, asset, Assignee, assume, assumed, Babson, Bachelor, barring, Bentley, bid, bill, blind, blinded, Bulletin, Cambrindge, capacity, cease, Clearline, College, consecutive, contractor, copy, correspondingly, CRO, deficiency, delisted, departure, depreciation, died, disability, discharge, dollar, dural, EMSCI, Exhibit, expedited, extinguishment, factor, family, filled, fiscal, flat, fourth, fractional, furniture, highest, holiday, hourly, impede, INPSIRE, input, insignificant, investor, Jeffrey, joining, Ladenburg, leaving, lender, Lincoln, list, listed, listing, LLC, long, low, marginal, master, McNulty, MD, Modestino, moratorium, myelotomy, NACTN, nearest, Neuro, newly, NLI, notion, Notwithstanding, offshore, OTC, Park, Patina, penny, pink, pioneering, preapproval, prepayment, proportionally, proportionately, provisional, Proxy, publicly, ratio, Reauthorization, reclassification, reconciling, regained, Region, repatriated, resignation, resigned, retroactive, retroactively, Richard, rollforward, SAB, Science, secondary, sexual, Shiseido, shown, single, sixteen, skew, stabilization, stranded, Subtopic, supplement, Task, taxation, Thalmann, titled, top, Toselli, transferred, treasurer, Trump, twenty, unissued, urge, Vice, wrote

Removed: amend, antidilution, Article, attributed, Brexit, cervical, chronic, compensate, conform, consumption, continually, Cosmetic, Council, country, create, CRISPR, decided, declared, Diagnostic, diluting, diversity, Dutch, electorate, epicenter, explained, feature, finalization, formally, framework, gene, Humanitarian, immaterial, informed, Institutional, intention, intrinsic, ISO, IVDR, Kingdom, leading, linguistic, Lisbon, marked, MDR, mission, notified, package, Parliament, partially, Presidency, pressure, procedure, reclassified, redefine, referendum, reflected, regime, renewed, replace, repricing, ScaffoldTM, schedule, shelf, simplify, subsidiary, text, Treaty, uncertainty, unrealized, Vitro, website, withholding, wrong

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

NVIVQ similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of InVivo Therapeutics Holdings Corp. (the “Company”) for the quarter ended March 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Richard Toselli, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.


Date: May 07, 2018	/s/ Richard Toselli
	Richard Toselli
	Chief Executive Officer (Principal Executive Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.